Research ArticleArticles
A Novel Selective Inverse Agonist of the CB2 Receptor as a Radiolabeled Tool Compound for Kinetic Binding Studies
Andrea Martella, Huub Sijben, Arne C. Rufer, Uwe Grether, Juergen Fingerle, Christoph Ullmer, Thomas Hartung, Adriaan P. IJzerman, Mario van der Stelt and Laura H. Heitman
Molecular Pharmacology October 2017, 92 (4) 389-400; DOI: https://doi.org/10.1124/mol.117.108605
Andrea Martella
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
Huub Sijben
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
Arne C. Rufer
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
Uwe Grether
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
Juergen Fingerle
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
Christoph Ullmer
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
Thomas Hartung
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
Adriaan P. IJzerman
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
Mario van der Stelt
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
Laura H. Heitman
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (A.M., H.S., A.P.I., L.H.H.), and Department of Molecular Physiology, Leiden Institute of Chemistry (A.M., M.S.), Leiden University, Leiden, The Netherlands; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (A.M., A.C.R., U.G., C.U., T.H.); and Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany (J.F.)
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticles
A Novel Tool Compound for CB2 Kinetic Binding Studies
Andrea Martella, Huub Sijben, Arne C. Rufer, Uwe Grether, Juergen Fingerle, Christoph Ullmer, Thomas Hartung, Adriaan P. IJzerman, Mario van der Stelt and Laura H. Heitman
Molecular Pharmacology October 1, 2017, 92 (4) 389-400; DOI: https://doi.org/10.1124/mol.117.108605
Research ArticleArticles
A Novel Tool Compound for CB2 Kinetic Binding Studies
Andrea Martella, Huub Sijben, Arne C. Rufer, Uwe Grether, Juergen Fingerle, Christoph Ullmer, Thomas Hartung, Adriaan P. IJzerman, Mario van der Stelt and Laura H. Heitman
Molecular Pharmacology October 1, 2017, 92 (4) 389-400; DOI: https://doi.org/10.1124/mol.117.108605
Jump to section
Related Articles
Cited By...
More in this TOC Section
Articles
Similar Articles
Advertisement